Nonalcoholic fatty liver disease(NAFLD)represents a major public health epidemic.Pharmacologic therapies for this condition are scarce,but multiple agents with novel mechanisms of action are in development.Here we rev...Nonalcoholic fatty liver disease(NAFLD)represents a major public health epidemic.Pharmacologic therapies for this condition are scarce,but multiple agents with novel mechanisms of action are in development.Here we review the pathophysiology and natural history of NALFD,diagnostic testing and data for currently available treatment strategies.We then turn our attention to promising developmental drugs and their respective trials.As the prevalence of fatty liver disease increases,clinicians will have more tools at hand for management of this condition.We conclude the horizon is bright for patients and doctors who deal with NAFLD.展开更多
Hepatitis C virus (HCV) infection affects as many as 185 million people globally,many of whom are chronically infected and progress over time to cirrhosis,decompensated liver disease,hepatocellular carcinoma,and event...Hepatitis C virus (HCV) infection affects as many as 185 million people globally,many of whom are chronically infected and progress over time to cirrhosis,decompensated liver disease,hepatocellular carcinoma,and eventually death without a liver transplant.In the United States,HCV genotype 1 constitutes about 75% of all infections.While interferon and ribavirin therapy was the cornerstone of treatment for many years,interferon-free treatments have become the standard of care with the emergence of new direct-acting agents,resulting in more effective treatment,shorter duration of therapy,better tolerability,lower pill burden,and ultimately better adherence.This review will summarize the evidence for the currently available combination therapies as well as emerging therapies in phase 3 trials for treatment of HCV genotype 1.展开更多
文摘Nonalcoholic fatty liver disease(NAFLD)represents a major public health epidemic.Pharmacologic therapies for this condition are scarce,but multiple agents with novel mechanisms of action are in development.Here we review the pathophysiology and natural history of NALFD,diagnostic testing and data for currently available treatment strategies.We then turn our attention to promising developmental drugs and their respective trials.As the prevalence of fatty liver disease increases,clinicians will have more tools at hand for management of this condition.We conclude the horizon is bright for patients and doctors who deal with NAFLD.
文摘Hepatitis C virus (HCV) infection affects as many as 185 million people globally,many of whom are chronically infected and progress over time to cirrhosis,decompensated liver disease,hepatocellular carcinoma,and eventually death without a liver transplant.In the United States,HCV genotype 1 constitutes about 75% of all infections.While interferon and ribavirin therapy was the cornerstone of treatment for many years,interferon-free treatments have become the standard of care with the emergence of new direct-acting agents,resulting in more effective treatment,shorter duration of therapy,better tolerability,lower pill burden,and ultimately better adherence.This review will summarize the evidence for the currently available combination therapies as well as emerging therapies in phase 3 trials for treatment of HCV genotype 1.
